Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring

Autor:	Wasmuth, J.C., Rodermann, E., Voigt, E., Vogel, M., Lauenroth-Mai, E., Jessen, A.B., Burger, D.M., Rockstroh, J.K.
Rok vydání:	2007
Předmět:	Invasive mycoses and compromised host [N4i 2] Infectious diseases and international health [NCEBP 13] Cognitive neurosciences [UMCN 3.2] Poverty-related infectious diseases [N4i 3] Clinical Pharmacology and physiology [CTR 2]
Zdroj:	European Journal of Medical Research, 12, 7, pp. 289-94 European Journal of Medical Research, 12, 289-94
ISSN:	0949-2321
Popis:	Item does not contain fulltext OBJECTIVE: To compare two reduced dose indinavir (IDV) + ritonavir (RTV) combinations guided by therapeutic drug monitoring (TDM) in treatment-naive HIV1-infected patients. METHODS: HIV1-infected treatment naive patients were prospectively randomized to treatment with IDV 600 mg or 400 mg BID each in combination with RTV 100 mg BID. Boosted IDV was combined with 2 NRTI, and patients were followed for 48 weeks. IDV-trough levels and initially also peak levels (C2h) were performed to allow dose modification of IDV following a specified protocol. RESULTS: 14 patients were randomized (age 38 +/- 10.4 years; mean +/- SD; 3 female, 11 male). 8 were treated with 600 mg (group 1), 6 with 400 mg IDV BID (group 2). Efficacy of treatment was good: CD4-cell count increased from 198/microl (14-523; median, range) to 371/microl (214-927) after 48 weeks (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::57ad37318a899cd1899b9ad215dc6e06 https://hdl.handle.net/2066/52089 Zobrazit plný text záznamu